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Diagnostic biomarkers (i.e. proteins) are often in low abundance in bodily fluids presenting many challenges
for their detection. In order to extend the application of SPRi systems in detecting biomarkers at ultralow
levels, we combine the advantage of aptamer technology with nanomaterials and microwave-assisted surface
functionalization. By implementing a sandwich assay through the introduction of aptamer-modified
quantum dots (QDs), it was possible to measure 7 zeptomole (at 5 fg/mL) of C-reactive protein (CRP)
selectively in spiked human serum. It is expected that the proposed platform will provide new direction in
designing ultrasensitive SPRi biosensors with multiplexing capabilities.
A
n ultrasensitive platform with simultaneous fast profiling of multiple low abundance protein biomarkers
from blood samples has the potential to provide a more comprehensive and accurate diagnosis/prognosis
of different types of human diseases, including cancer, cardiovascular and neurological disorders. More
importantly, a diagnostic biomarker should be able to highlight the early onset of a disease prior to the appearance
of clinical symptoms to ensure a greater therapeutic efficacy. Based on these prerequisites, the detection platform
should have super ultrasensitivity (below pg/mL), as biomarker levels in biological fluids are extremely low, to
date, conventional platforms are unable to provide such ultrasensitivity in combination with multiplexing.
Enzyme linked immunosorbent assay (ELISA) is a commonly used technique for biomarker detection; it
provides good sensitivity (pg/mL or femtomolar (10215) range), excellent specificity, and low coefficient of
variation (2–5%)1. However, the optimization of these assays is labor intensive, requires large amounts of sample
in development and use, and can only target a single protein per assay. In addition, antibodies (recognition
elements) in ELISA present practical limitations such as low stability and high production cost. An alternative
recognition probe to antibodies are synthetic single stranded DNA/RNA aptamers which offer a large degree of
specificity, high affinity, easy-to-perform modification, low cost and a rapid turnaround for production. Recently,
aptamer-based biosensors exploiting detection by means of electrochemical2, optical3 and mass-sensitive trans-
ducers4,5 have been developed. Of these assay formats, surface plasmon resonance imaging (SPRi) is the most
advanced label-free optical/mass-sensitive technology for detecting biomolecular interactions in situ and in real
time with high throughput.
SPRi is an optical technique that monitors refractive index changes at the metal/dielectric media interface. A
high refractive index prism coated with a thin layer of gold (50 nm) couples the incident light (p-polarized) to the
propagating surface plasmons at a specific angle and wavelength6. Any perturbation to the sensor surface modifies
the resonance conditions causing intensity variations of the reflected light at a fixed angle. The reflected light is
then intercepted by a charge-coupled device (CCD) camera allowing for the visualization of multiple interactions
simultaneously on the sensor chip in real time together with the relative sensorgram. The kinetic sensorgram plots
the percent change in reflectivity versus time.
There have been significant advancements in SPR-based biosensors in the last two decades, however, mea-
suring ultra-low levels (sub-ng/mL) of biomarkers in bodily fluids still remains a challenge. To this end, a number
of amplification techniques combining proteomics7 and genomics8–10 with nanomaterials have been proposed to
increase the signal, or optical contrast, generated by the binding event in SPR. For example, one strategy involves
utilizing a sandwich-immunoassay type complex through the inclusion of gold nanoparticles in the sensing layer
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amplification is attributed to the coupling of localized surface plas-
mon resonance with SPR and a mass loading effect13. Other strategies
take advantage of the coupling of fluorescent probes such as
quantum dots (QDs) to metallic surfaces14–16. Plasmonic field effects
are known to improve the emission from fluorescent probes by sev-
eral fold to produce highly directional and polarized emissions17.
Moreover, the refractive index near the plasmonic surface is modi-
fied because of the presence of the fluorescent probes, thus affecting
the excitation and propagation of the plasmon wave18,19. Recently, we
have reported that the integration of near-infrared (NIR) QDs with
SPRi enhanced the limit of detection (LOD, pg/mL)15 due to a mass
loading effect and spontaneous emission coupling with propagating
surface plasmons.
In the present communication, we introduce an ultrasensitive
SPRi-based nano-aptasensor for the detection of C-reactive protein
(CRP) at 5 fg/mL (43 aM [10218 M] and/or 7 zeptomole [10221
moles, (assay volume of 150 mL)]) level in spiked human serum.
This ultrasensitive system was engineered through the unique integ-
ration and combination of the SPRi platform with microwave-
assisted surface chemistry, aptamer technology and NIR QDs, to
create a clinically relevant biosensor. CRP is a general inflammatory
biomarker and useful in diagnosing inflammatory responses in can-
cer20, cardiovascular diseases21 and neurological disorders22. In this
study, CRP was simply employed as a model biomarker. To accur-
ately diagnose most human diseases, panels of biomarkers need to be
profiled simultaneously at real time with high sensitivity. Due to the
Figure 1 | Binding of CRP to sensor chip using conventional or microwave-assisted surface functionalization. A plot comparsion of the SPRi kinetic
signal after the injection of CRP (2 mg/ml) in buffer (10 mM TRIS, 15 mM NaCl, 2 mM CaCl2 pH 7.4) onto a gold-coated prism that has been coated
with Cystamine/Glutaraldehyde in the (a) absence and (b) the presence of microwave-assisted irradiation and followed by the functionalization of
aminated CRP-specific and control aptamer. Both surfaces were blocked with BSA prior to injection of CRP. (c) A comparison of the equilibrium
dissociation constant (KD) between microwave and conventional treated surface to the binding response of CRP.
Figure 2 | CRP binding to sensor chip blocked with BSA or PEG-SH. A plot comparison of the SPRi kinetic signal after the injection of CRP (2 mg/ml) in
buffer (10 mM TRIS, 15 mM NaCl, 2 mM CaCl2 pH 7.4) onto a gold-coated prism that has been functionalized with biotinylated CRP-specific and
control aptamer followed by blocking with (a) BSA and (b) PEG-SH. (c) A comparison of the equilibrium dissociation constant (KD) between BSA and
PEG-SH treated surface to the binding response of CRP.
www.nature.com/scientificreports
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innate capabilities of the SPRi instrument for multiplexing and the
proposed nano-aptasensor attomolar sensitivity, one can foresee the
potential of extending this proposed platform to detect in real-time
proteinaceous and non-proteinaceous molecules found in blood,
urine, cerebrospinal fluid and other specimens that are indicative
and even predictive of disease onset and progression.
Results
Microwave-assisted surface functionalization. In general, for a
SPRi biosensor, the functionalization of chemical linkers on the
surface of the gold-coated chip serves to provide means of
attaching the capture probe. Conventional immobilization
procedures using Cystamine/Glutaraldehyde (Cys/Glu) layers
requires over 3 hours prior to introduction of the capture probe.
In this study, we compared conventional methods with
microwave-assisted surface functionalization of Cys/Glu to assess
their influence on the binding interaction between the capture and
target probe. In all SPRi experiments, the change in reflectivity
(%DR) was calculated by taking the difference between the initial
and final buffer signals. As Fig. 1 shows the microwave treated
chip had a significantly larger signal change (% D R, 2 fold
increase) after injection of CRP (a model biomarker) than the chip
that was prepared through the conventional method. The calculated
equilibrium dissociation constant (KD, Fig. 1c) of the CRP aptamer
decreased two order of magnitudes resulting in a stronger binding
interaction. Microwave-assisted surface functionalization not only
improved the detection of CRP and avidity using SPRi but also
decreased the functionalization procedure from several hours to
minutes.
Blocking agent influence and optimization. In addition to the
immobilization of a chemical linker directly onto the gold surface
for subsequent attachment of probes, the overall goal is to engineer a
support construct that provides large degree of accessibility to the
target probe while retaining good stability and minimizing capture
probe detachment and non-specific binding. Extravidin was selected
as the direct chemical linker to the capture probe in order to take
advantage of its strong binding affinity to biotinylated probes, as well
Figure 3 | A schematic illustration of the sandwich protocol implemented for the detection of CRP in biological fluid. The gold-coated prism is pre-
functionalized with aptamers specific to CRP and control aptamers followed by the (a) direct detection of CRP (fg/ml) spiked in human serum and the (b)
sandwich based assay using CRP-Specific_aptamer-coated QDs for SPRi signal amplification. Direct detection of CRP (fg/ml) does not generate a
quantifiable sensor response as depicted with no change in the angle of reflectivity, however, with sandwich assay the NanoEnhancers induce a change in
the reflectivity.
www.nature.com/scientificreports
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as its superior antifouling properties against human serum proteins.
After the formation of the Cys/Glu layer, the gold surface was
blocked with chemicals to prevent any non-specific adsorption
from serum proteins. To this end, we compared two commonly
used blocking agents, bovine serum albumin (BSA) and
poly(ethylene glycol) methyl ether thiol (PEG-SH). After direct
binding of the capture probe (biotinylated CRP_Specific Aptamer)
to an extravidin coated surface, followed by injection of CRP in
buffer, the PEG-SH had a greater SPRi response than BSA
(Fig. 2a–b). When comparing their binding affinity both exhibited
similar values (Fig. 2c), however, PEG-SH provided better
accessibility for CRP to bind to the immobilized aptamer.
Determination of SPRi limit of detection for CRP in human
serum. Our final construct for the detection platform involved
using a microwave-assisted Cys/Glu coated gold chip that was
immobilized with extravidin for direct attachment of the capture
probe (biotinylate CRP_specific aptamer). The sensor chip was
further blocked by injecting PEG-SH inside the instrument.
Following the injection of a solution of CRP spiked in 1% human
serum, an intense SPR signal response with a weak association and
shortly after an abrupt signal drop (Supplementary Fig. S1) were
observed. The intense SPR response is due to the high refractive
index difference between the running buffer and the serum. In
addition, it could be attributed to weak non-specific interaction of
serum proteins. Therefore, using the direct detection method for
CRP spiked in human serum is challenging, as one cannot
precisely quantify the amount of CRP (Fig. 3a).
To overcome this challenge, we designed a sandwich based assay
that uses CRP_specific Aptamer coated NIR QDs (NanoEnhancers)
to amplify the signal for the SPRi sensor (Fig. 3b). As shown in
Fig. 4a, the introduction of the NanoEnhancers to a pre-injected
solution of CRP (500 ng/mL) in human serum resulted in 17.85 6
0.54 (%DR), while the control sample had minimal change (%DR 5
1.74 6 0.22). In addition, a difference image (Fig. 4b) was recorded to
correlate the binding kinetics after injection of NanoEnhancers. The
spots that have been pre-functionalized with CRP_specific Aptamers
(left) are intensely illuminated as opposed to control aptamers spots
(right). The correlation between the binding kinetics and the differ-
ence images (plot profile) helps further validate the binding inter-
action between aptamer-CRP and NanoEnhancers. The formation of
the NanoEnhancers-CRP complex (KD 5 169 pM 6 1.6) resulted in
higher affinity in comparison to the formation of Aptamer-CRP
complex (KD 5 5.76 nM 6 1.01). Furthermore, we examined the
influence of BSA in the sandwich based assay format and found that
there was no signal enhancement after the addition of the
nanoEnhancers (Supplementary Fig. S2).
To further investigate the reliability of the biosensor in distin-
guishing different amounts of CRP present in human serum, we
assessed the sensor performance with a range of CRP concentrations.
A decrease in SPRi signal was observed as the amount of CRP spiked
in human serum was lowered (Fig. 5a). To further assess the robust-
ness of our platform, serum concentration was increased from 1% to
20%. A complementary response was observed after the injection of
500 pg/ml of CRP in 20% serum (Supplementary Fig. S3) in com-
parison to the corresponding experiment performed in 1% serum
(Fig. 5a). Examining the extended range of the concentration gra-
dient curve in Figure 5b, the detection platform exhibited a biphasic
response that can be interpreted as the result of two binding sites with
different affinities. The biphasic response is common with SPR sen-
sors when proteins multimerize. In our case, CRP in the presence of
calcium, conforms to a pentameric structure23, as a result, two bind-
ing sites with different affinities are observed. However, at the lower
concentration range, the detection platform exhibited a linear trend
in the region from 5 fg/mL to 5000 fg/mL (Supplementary Fig. S4).
The LOD was validated to be 5 fg/mL, this in agreement with the
LOD having a 3-fold higher response than the control, when taken
into consideration the standard error (inset, Fig. 5b).
Discussion
Microwave assisted chip-surface modification offers fast turnaround
time and a stronger support structure for the capture probe. The
acceleration in reaction time with microwave irradiation24, in com-
parison to conventional methods, is due to the conversion of elec-
tromagnetic energy into heat, rendering a robust SPRi sensor with
better sensitivity and avidity. In addition, the aptamer binding affin-
ity was comparable to CRP antibodies25. We have found that the type
of blocking agent used greatly influences the capture probe inter-
action with analyte, as well as with the NanoEnhancers. For potential
clinical applications of SPRi, much effort was spent in optimizing the
surface chemistry of the sensor; the combination of PEG-SH/
Extravidin26 and microwave-assisted functionalization with Cys/
Glu was found to significantly improve the efficiency and perform-
ance of the biosensor.
Figure 4 | Detection of CRP using a sandwich assay spiked in human
serum. (a) Binding of NanoEnhancers (CRP_specific_Aptamer-QDs)
after the injection of PEG-SH and CRP (500 pg/ml) spiked in human
serum to Cys/Glu/extravidin/Aptamer surface coated gold chip and (b)
SPRi difference images showing the binding of NanoEnhancers to CRP
(left) and control (right). (c) A plot profile of the SPRi difference image
revealing intensity values to the area indicated by the yellow line in
figure 4b and shows the change in contrast due to the binding of
NanoEnhancers in spots functionalized with CRP_Specific aptamer (left,
A1–A5), control aptamer (right, C1–C5). The middle region of the line is
the background.
www.nature.com/scientificreports
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There are several challenges in directly detecting biomarkers in
human serum using the SPRi platform, because the direct response
from the binding of biomarker to the sensor surface can be masked
by non-specific interactions from sera proteins (higher in concen-
tration than desired biomarker), changes in the refractive index of
injected solution from the running buffer, and analyte concentration
falling below the LOD of the instrument. To overcome these obsta-
cles, we employed a sandwich-amplification strategy using
NanoEnhancers that allowed us to detect CRP (model biomarker)
in human serum at a LOD of 43 attomolar (5 fg/mL). Many prev-
iously reported strategies utilize gold nanoparticles in complex sam-
ples11,12,27 or buffered conditions18,28,29 to amplify the SPR signal for
detection of biomolecules; however, the level of sensitivity attained
with our platform is by far superior. Previously, we reported the use
of NIR QDs for signal amplification of prostate specific antigen
(PSA) using antibodies as capture probes and PEG-COOH/PEG-
OH as the surface coating and attained a LOD of 2.5 ng/mL. In the
present work, we employed aptamers as opposed to antibodies15 to
serve as the capture probe. We have found that by using aptamers in a
sandwich assay, sensitivity of the sensor is improved, as observed by
Kim and co-workers4. We attribute this increase in sensitivity to a
decrease in the separation distance between the QDs and the sensor
surface, as a result of the aptamer folding from a single stranded
DNA to tertiary structure after binding to analyte, or perhaps due
to differences in length between aptamer and antibody. In addition,
we observed that the aptamers conjugated on quantum dots
(NanoEnhancers) experienced a one order of magnitude improve-
ment in affinity compared to its parent aptamer (immobilized cap-
ture molecule). This enhancement could be a result of several
aptamers and CRP binding30. Increasing the serum concentration
Figure 5 | A sandwich assay using NanoEnhancers for the detection of CRP spiked in human serum. (a) Normalized SPRi kinetic plot representation of
CRP_specific_Aptamer-QDs-amplified signal for human serum samples spiked with different concentrations of CRP. A vertical dashed line (grey)
represents the injection point of the running buffer. (b) A concentration gradient curve representing the binding of NanoEnhancers
(CRP_specific_Aptamer-QDs) after the injection of various amounts of CRP spiked in human serum to the sensor surface that has been prefunctionalized
with biotinylated CRP-specific (black) and random aptamer as a control (red). The inset figure depicts the percent change in reflectivity (%DR) after
introduction of NanoEnhancers for 5 fg/ml, 50 fg/ml and 5000 fg/ml.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5129 | DOI: 10.1038/srep05129 5
from 1% to 20% did not affect the percent change in reflectivity after
the addition of NanoEnhancers. However, to minimize non-specific
binding from excess proteins present in the sample, the salt concen-
tration in the running buffer was increased from 15 mM to 250 mM.
The exact mechanism behind NIR QDs SPRi signal enhancement
is still not very well understood, however, few hypotheses could be
presented here. One hypothesis alludes to a mass loading effect and
the other suggests NIR fluorophores will couple the scatter light more
strongly onto gold film nanostructures31. Nanometer thick gold film
have a stronger absorption32 in the NIR as opposed to the visible
range. As highlighted in our previous work15, the visible red emitting
quantum dots (550–650 nm) had a lower SPR amplification signal
than the NIR quantum dots (800 nm). Furthermore, Wei et al.19
refers to a bidirectional relationship between QDs and SPs on a silver
nanowire, where energy is transferred from propagating SPs to the
excitons and the excited QDs prompt the generation of propagating
surface plasmons in the silver nanowires. All above mentioned work
suggest that metallic film-QD heterostructures experience unique
interactions that we are still in the process of exploring greatly to
further understand their principal mechanism and applications.
Finally, this work highlights and establishes the ability of SPRi sen-
sors to achieve zeptomole sensitivity in biological fluids as a result of
combining NIR QDs with smart surface engineering.
Methods
Chemicals and reagents. Cystamine dihydrochloride (Cys), glutaraldehyde solution
25% (Glu), phosphate buffered saline (PBS), poly(ethylene glycol) methyl ether thiol
(PEG-SH), bovine serum albumin (BSA), extravidin were purchased from Sigma-
Aldrich(St. Louis, MO, U.S.A.). Calcium chloride anhydrous (CaCl2), sodium
chloride (NaCl), TRIS base for molecular biology and ethanol were all purchased
from Fischer Scientific. Nanostrip was purchased from Cyantek. Biotinylated
CRP_specific Aptamer was purchased from OTC Biotech. Biotinylated control
aptamer with the following sequence 59-GGGCCTCCGGT -TCATGCCGC-39 was
purchased from Integrated DNA technologies. QDot 800 streptavidin conjugate was
purchased from Life Technologies.
SPRi gold chip cleaning. The gold-coated prism (Horiba Scientific, France) was
sonicated in water for 30 minutes at 50uC and then rinsed with ethanol and dried in
the oven (60uC). To remove any organic contaminants, the gold-coated prism was
then immersed in nanostrip and then heated to 50uC under sonication for 90 minutes.
The solution was then allowed to cool to room temperature and then the prism was
removed and rinsed with water to remove excess Nanostrip followed by sonication in
water (50uC) for 30 minutes. The prism was then given a final wash with ethanol and
dried with nitrogen. Finally, the prism was then placed into a UV Ozone Cleaner
(ProCleanerTM Plus from Bioforce Nanosciences) for 20 minutes. If it is not noted
below after the formation of each layer, the biochip was excessively rinsed with water
and then dried with nitrogen.
Conventional surface functionalization. To bind biotin-labeled aptamers onto the
gold surface, we used Cystamine/Glutaraldehyde/Extravidin surface chemistry. In
Brief, the biochip was immersed in 25 mM cystamine in 90% ethanol for 2 hrs and
washed with ethanol. Afterwards, a second layer was formed by dipping the chip in a
2.5% solution of glutaraldehyde for 1 hr. Finally, extravidin (0.2 mg/mL diluted in
PBS, pH 7.4) was deposited on the chip and incubated for one hour in a humid
environment and rinsed with water followed by drying with nitrogen. Biotin-labeled
CRP and control aptamers (10 mM) suspended in 10% glycerol were spotted
(300 mm) using a SPRi Arrayer (Horiba Scientific) onto the surface and left to
incubate for 2 hours at a humidity of at least 75%.
Microwave-assisted surface functionalization. A cleaned gold-coated chip was
immersed in a solution of cystamine (25 mM in 90% ethanol) and then microwave
irradiated (50 watts, 5 minutes, 50uC) using a CEM discover Labmate. Afterwards, the
prism was rinsed and soaked for 5 minutes in 90% ethanol. The second layer
formation involved depositing the chip in a 2.5% glutaraldehyde solution and
irradiated with the same microwave settings as described with cystamine. A solution
of extravidin (0.2 mg/mL diluted in PBS buffer, pH 7.4) was deposited on the chip
surface. Spotting of the biotinylated aptamers was done in the same manner as
described in the conventional surface functionalization section above.
SPRi measurements. SPRi measurements were performed using SPRi Lab1
instrument equipped with an 800 nm laser, CCD camera, peek flow cell,
programmable syringe pump (Harvard Apparatus PHD 2000) and an injection loop
of 150 ml (Horiba Scientific, France) placed in a Memmert Peltier-cooled incubator
(model IPP 500, Wisconsin Oven Distributors, USA) for temperature stabilization.
The entire prism surface was monitored during the experiments; spots with a
diameter of 300 mm were chosen to determine total reflectance change that indicates a
binding event occurrence. For each injection, 40 SPRi signals were collected,
background subtracted automatically and averaged using the ScrubberGen Software.
Each kinetic curve corresponds to an average curve of 20 spots for CRP-Specific
Aptamer and 20 spots for the control. The reproducibility of each measurement was
thus expressed as percent change in reflectivity on the 40 SPRi signals relative to each
sample injected on four different biochips (n 5 4). Reflectance change was monitored
at the angle that is determined to be the highest slope of the plasmon absorption. The
kinetics analysis was performed by plotting percent change in reflectivity (%DR)
against time to illustrate the binding events. The SPRi difference images taken by the
CCD camera were collected at real time to monitor the reactions occurring on the
surface of the chip. The binding event was observed as an increase in the reflected
intensity, regarded as a bright spot, which is easily distinguishable from the
background (black). The reported curves are the average of 20 spots (background 5
blocked surface reflectance change subtracted), each experiment has been repeated
four times. The difference images were then used to show the reflectivity change to
further confirm that a binding event has occurred. To retain the pentameric structure
of CRP, the running buffer contained calcium. Protein binding experiments were
performed at a flow rate of 5 ml/min using a running buffer of 10 mM Tris, 15 or
250 mM NaCl (the former concentration was used in 1% serum experiment and the
latter in 20% serum experiment), 2 mM CaCl2 at pH 7.4. The prism was then blocked
with an injection of 10 mM PEG-SH or 1% BSA followed by a running buffer rinse.
The SPRi was then calibrated by injecting a sample of the running buffer that has a 25
or 260 mM NaCl concentration instead of the normal 15 or 250 mM. This injection
causes an increase in reflectivity due to the change in the dielectric constant. A
calibration factor for each plot was then calculated and used to adjust all of the plots to
the same change in reflectivity. CRP in running buffer or spiked in 1% or 20% human
serum was then injected. For all sandwich assays, 10 nM of Streptavidin Qdot 800 was
reacted with biotinylated CRP_Specific Aptamer (NanoEnhancers) for 30 minutes
prior to injection. The NanoEnhancers were diluted with running buffer prior to
injection into the SPRi system. Finally, %DR was computed by taking the difference
between pre and post NanoEnhancers or protein injection (initial and final buffer
signals). The reported limit of detection (LOD) represents the minimum detectable
target concentration for which the SPRi signal (%DR) was at least three times higher
than that of the control. Equilibrium dissociation constants (KD) were calculated
using the ScrubberGen software.
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